期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

促红细胞生成素治疗糖尿病肾病预防左心室重构进展 被引量：2

Progress in prevention of left ventricular remodeling by erythropoietin of treating diabetic nephropathy
下载PDF
导出
摘要 糖尿病肾病(DN)早期会造成肾性贫血,而贫血导致左心室的重构和心功能的改变。促红细胞生成素(EPO)不仅有促进造血的作用,还具有潜在的组织和细胞保护作用。改善贫血可使DN患者的心脏左心室质量指数(LVMI)得到改善,从而起到改善患者心功能的作用,为临床DN心脏重构的早期预防和早期治疗提供了新的思路和方法。随着研究的不断深入,EPO可能在DN的临床治疗中发挥重要作用。 Early diabetic nephropathy results in renal anemia,and anemia leads to the change of left ventricular remodeling and cardiac function.Erythropoietin not only promote the effect of blood,but also has potential protective effect on tissues and cells,it has been researched in the cardiovascular system diseases.LVMI of patients with DN will be advanced by changing anemia,and it provides new ideas and methods for early prevention and treatment of clinical cardiac remodeling,with the continuous deepening of the study,EPO may play an important role in the clinical treatment of DN.
作者 杨巍 蔡彦 黄翰凡 周燕
机构地区 南宁市红十字会医院心内科
出处 《实用药物与临床》 CAS 2010年第2期131-134,共4页 Practical Pharmacy and Clinical Remedies
基金 2010年广西自然科学基金(2010JJA40071)
关键词 促红细胞生成素 糖尿病肾病 预防 左心室重构 Erythropoietin Diabetic nephropathy Prevention Left ventricular remodeling
分类号 R692.9 [医药卫生—泌尿科学]
  • 相关文献

参考文献29

  • 1Hayashi T,Suzuki A,Shiji T.Cardiovascular effect of normalizing the hematocdt level during erythropietin therapy in predialysis patients with chronic renal failure[J].Am J Kidney Dis,2000,35 (2):250-252.
  • 2占锦峰,刘志红,谢红浪,葛永纯,张培培,张馨,鲍浩,黎磊石.糖尿病肾病患者贫血的特点及其相关因素分析[J].肾脏病与透析肾移植杂志,2007,16(6):516-521. 被引量：18
  • 3刘玉才.福辛普利与辛伐他汀单用或联合治疗糖尿病肾病疗效观察[J].中国医药,2008,3(9):533-535. 被引量：7
  • 4张益民,叶任高.慢性肾性贫血的血红蛋白和血细胞压积的治疗目标[J].中国中西医结合肾病杂志,2003,4(8):454-454. 被引量：6
  • 5Ezekowitz J,Mc Alister FA,Hunphries KH,et al.The association among renal insufficiency,pharmacotherapy,and outcomes in 6427 patients with heart failure and coronary artery disease[J].J Am Coll Cardio,2004,44:1587-1592.
  • 6Sarnak MJ,Leey AS,Schoolwerth AC,et al.Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease,High Blood Pressure Research,Clinical Cardiology,and Epidemioiogy and Prevention[J].Circulation,2003,108:2154-2169.
  • 7Jurkovitz C,Abramson J,Mccellan WM.Anemia and cardiovascular and kidney diseases[J].Curr Opin Nephrol Hypertens,2006,15 (2):117-122.
  • 8Dowling TC.Prevalence,etiology,and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease:an overview[J].Am J Health Syst Pharm,2007,64 (13suppl8):S3-7,quiz S23-25.
  • 9Silverberg DS,Wexler D,Iaina A,et al.The importance of anemia and its correction in the mamagement of severe congestive heart failure[J].Eur J Heart Fail,2002,4(6):681-686.
  • 10Silvetberg DS,Wexler D,Slieps D,et al.The effect of correction of mild anemia in severe,resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron:a randomized controlled study[J].J Am Coll Cardio,2001,37:1775-1780.

二级参考文献12

  • 1Levey AS, Greene T, Kusek JW, et al. A simplifyied equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol, 2001, 11 : A0828 (abstract).
  • 2Rossing P, Rossing K, Gaede P, et al. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care, 2006, 29: 1024- 1030.
  • 3Thomas MC, Thomas M, Tsalamandris, Maxzsaac, et al. Anemia in diabetes : an emerging complication of microvaseular disease. Current Diabet Rev, 2005, ( 1 ) : 107 - 126.
  • 4Sinclair SH. Diabetic macular edema: New concepts of pathology and treatment. Semin Ophthalmol, 1999, 14: 197- 199.
  • 5Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neo- vascularization in vivo by inhibition of vascular endothelial growth factor (VEFG) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA,1995, 92:10457 - 10461.
  • 6Friedman EA, LEsperance FA, Brown CD, et al. Treating azotemiainduced anemia with erythropoietin improves diabetic eye disease. Kidney Int,2003, (Suppl) (87), S57 - 63.
  • 7Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythrepoietin. Retina, 1994, 14 : 1 - 5.
  • 8Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Didney Dis, 1995,26: 202 - 208.
  • 9Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in nor- motensive men with wen-controlled type 2 diabetes: importantce of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care, 2001,2:5 - 10.
  • 10Sarnak MJ, Leey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease. High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation, 2003,108 : 254 - 2169.

共引文献43

同被引文献23

  • 1何冰,韩萍,吕先科.2型糖尿病患者急性时相蛋白与糖尿病肾病的关系[J].中华内分泌代谢杂志,2003,19(4):260-262. 被引量：170
  • 2吴国仲,吴永贵.糖尿病肾病发病炎症机制研究进展[J].国外医学（泌尿系统分册）,2005,25(3):363-367. 被引量：46
  • 3姜华军,刘建社,朱忠华,王全胜,张晓丽,王玉梅,冯玉锡.坎地沙坦对糖尿病肾病小鼠血清和糖皮质激素诱导的蛋白激酶1表达的影响及意义[J].中国药理学通报,2006,22(5):547-551. 被引量：20
  • 4American Diabetes Association. Standards of medical care in diabetes-2006[J].Diabetes Care,2006,29(Suppl 1) S4-S42.
  • 5Detoumay B, Cross, Charbonnel B, et al. Managing type 2 diabetes in France:the ECODIA survey [J].Diabetes Metab, 2000,26(5) :363-369.
  • 6Schauer P R, Burguera B, Ikramuddin S, et al. Effect of laparoseopic Rous-en-'Y gastric bypass on Type 2 diabetes mellitus [J]. Ann Surg, 2003,238 (4) : 467-484 ; discussion 84- 85.
  • 7Rubino F, Gagner M. Potential of Surgery for Curing Type 2 Diabetes Mellitus [ J ]. Ann Surg, 2002,236 (5) : 554-559.
  • 8Buteau J, E1-Assaad W, Rhodes C J. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity [J]. Diabetologia,200d,47 (5) :806-815.
  • 9Shi Y H, Duan H J, Wang L H, et al. Effects of losartan on the expression of STAT1 in glomeruli of diabetic rats [J]. Chin Pharmacol Bull, 2005,21 (3) : 323-326.
  • 10Gounmenos D S, Tsakas S, El Nahas A M, et al. Transforming growth factor-β1 in the kidney and urine of patients with glomerular disease and proteinuria [J]. Nephrol Dial Transplant, 2002,17(12) :2145.

引证文献2

二级引证文献6

实用药物与临床
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部